Viewing Study NCT07466303

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:16 PM
Ignite Modification Date: 2026-06-11 @ 4:35 AM
Study NCT ID: NCT07466303
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-12
First Post: 2026-02-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Sponsor: Xijing Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Neoadjuvant Therapy View
None Pathological Complete Response View
None Serplulimab View
None PD-1 Inhibitor View
None Antibody-Drug Conjugate View
None Trastuzumab Deruxtecan View
None Phase II Clinical Trial View
None Triple-Negative Breast Cancer View
None HER2-Low Breast Cancer View